FDA Clears P-tau217 Blood Tests; Lilly and Roche Collaborate on Biomarker Development
1 report, 1 independent
Updated Fri 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The Food and Drug Administration has cleared two P-tau217 blood tests for use. The FDA is also collaborating on the development of blood-based biomarker tests. These tests are being developed with the goal of helping to rule in and rule out Alzheimer’s pathology.
From meddeviceonline.com
Why it matters
This development could reshape Alzheimer’s diagnosis by moving testing away from specialized, costly procedures toward a faster, more accessible blood draw. The collaboration between Eli Lilly and Roche Diagnostics aims to advance this technology in the clinical landscape.
From meddeviceonline.com
Who's involved
- FDARegulatory body whose oversight is required for the market access of medical devices.
- Eli Lilly and CompanyPartnering with Roche Diagnostics on the development of blood-based biomarker tests.
- Roche DiagnosticsManufacturer of the Elecsys pTau217 test and collaborator with Eli Lilly on new diagnostic methods.
Keep exploring
The entities involved
- FDA
-
Eli Lilly and Company
American pharmaceutical company
-
Roche Diagnostics
Swiss diagnostic company
Nothing else this week.